ezogabine has been researched along with Aura in 49 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (8.16) | 18.2507 |
2000's | 11 (22.45) | 29.6817 |
2010's | 28 (57.14) | 24.3611 |
2020's | 6 (12.24) | 2.80 |
Authors | Studies |
---|---|
Amato, GS; Burns, JF; Eargle, CW; Fritch, PC; Harrison, W; Jones, L; McNaughton-Smith, G; Roeloffs, R; Wickenden, AD | 1 |
Du, X; Fu, Y; Jia, Q; Mi, Y; Qi, J; Wang, K; Wu, Y; Xu, W; Zhang, D; Zhang, F; Zhang, H | 1 |
Arora, G; Baker, K; Boscoe, BP; Butler, CR; Chenard, L; Claffey, MM; Clark, AJ; Davoren, JE; DeNinno, SL; Drozda, SE; Duplantier, AJ; Lowe, JA; Mather, RJ; Moine, L; Reese, MR; Rogers, BN; Rong, H; Rong, S; Schuyten, K; Serpa, KA; Snow, SL; Stolyar, P; Tse, K; Weber, ML; Whisman, TL; Wright, AS; Zhang, L | 1 |
Lu, D; Ouyang, P; Yang, S | 2 |
Bakshi, T; Bhamidipati, R; Brady, P; Cato, M; Chapman, M; Chaudhary, KW; Donovan, B; Dougherty, RW; Downie, D; Fu, T; Higgins, GA; Holenz, J; Kuppusamy, BM; Lin, H; Lluel, P; Madhyastha, N; Matsuoka, Y; Mohd, Z; Morrow, D; Pasikanti, K; Rajagopal, S; Rouget, C; Samanta, SK; Seefeld, MA; Zhen, W | 1 |
Bialer, M; Johannessen, SI; Koepp, MJ; Levy, RH; Perucca, E; Perucca, P; Tomson, T; White, HS | 1 |
Bleakley, LE; McKenzie, CE; Reid, CA | 1 |
Kelly, M; Knight, D; Mahida, S; Olson, HE; Poduri, A | 1 |
Dong, H; Feng, S; Lin, L; Liu, Y; Shi, G; Tian, Y; Zhao, F | 1 |
Allison, WT; Kanyo, R; Kurata, HT; Li, J; Locskai, LF; Wang, CK | 1 |
Ambrosino, P; Binda, A; Canafoglia, L; Castellotti, B; DiFrancesco, JC; Freri, E; Gellera, C; Granata, T; Labalme, A; Lesca, G; Messina, G; Mosca, I; Murano, C; Ragona, F; Rivolta, I; Solazzi, R; Soldovieri, MV; Taglialatela, M; Vannicola, C | 1 |
Ambrosino, P; Manocchio, L; Miceli, F; Mosca, I; Soldovieri, MV; Taglialatela, M | 1 |
Gautier, NM; Glasscock, E; Mishra, V; Vanhoof-Villalba, SL | 1 |
Gao, Z; Gu, M; Li, M; Nan, FJ; Yu, H; Zhou, P | 1 |
Ilickovic, I; Jankovic, S | 1 |
Hatch, RJ; Petrou, S; Reid, CA | 1 |
Bell, GS; Chinnasami, S; Duncan, JS; Novy, J; Sander, JW; Wehner, T | 1 |
Bocchicchio, M; Huber, B | 1 |
Duignan, KM; Edwards, S; Furuya, T; Kalappa, BI; Soh, H; Tzingounis, AV; Tzounopoulos, T | 1 |
Lopez-Garcia, JA; Rivera-Arconada, I; Vicente-Baz, J | 1 |
Lerche, H; Maljevic, S; Seebohm, G; Wuttke, TV | 1 |
Deeks, ED | 1 |
Szupera, Z | 1 |
Gunthorpe, MJ; Large, CH; Sankar, R | 1 |
Crean, CS; Gunthorpe, MJ; Large, CH; Nehlig, A; Sankar, R; Sokal, DM; Vanlandingham, KE; White, HS | 1 |
Chabwine, JN; Démonet, JF; du Pasquier, RA; Hirt, L; Kuntzer, T; Michel, P; Rossetti, AR; Schluep, M; Vingerhoets, FG | 1 |
Berry, DJ; Patsalos, PN | 1 |
Forcelli, PA; Gale, K; Kondratyev, A; Lakhkar, A; Soper, C | 1 |
Mula, M | 1 |
Lerche, H; Nies, AT; Orhan, G; Schwab, M; Wuttke, TV | 1 |
Hopkins, CR | 1 |
Kumar, M; Kumar, R; Verma, A | 1 |
Brandt, C; Ebert, U; Löscher, W | 1 |
Dworetzky, SI; Wua, YJ | 1 |
Blackburn-Munro, G; Blackburn-Munro, RE; Dalby-Brown, W; Mikkelsen, JD; Mirza, NR | 1 |
Green, AC; Harrison, PK; Sheridan, RD; Tattersall, JE | 1 |
Nohria, V; Porter, RJ; Rundfeldt, C | 1 |
Kwon, YS; Mazarati, A; Sankar, R; Shin, D; Wu, J | 1 |
Adams-Curtis, LE; Cheong, JH; Dailey, JW; Jobe, PC; Ko, KH | 1 |
Bialer, M; Johannessen, SI; Kupferberg, HJ; Levy, RH; Loiseau, P; Perucca, E | 1 |
Armand, V; Heinemann, U; Rundfeldt, C | 2 |
Rundfeldt, C | 1 |
Dost, R; Rundfeldt, C | 1 |
Lawson, K | 1 |
Cooper, EC | 1 |
15 review(s) available for ezogabine and Aura
Article | Year |
---|---|
Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites.
Topics: Animals; Carbamates; Epilepsy; Humans; Indoles; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Membrane Transport Modulators; Neurons; Phenylenediamines; Potassium Channel Blockers; Pyridines | 2018 |
KV7 channelopathies.
Topics: Animals; Carbamates; Channelopathies; Epilepsy; Humans; KCNQ Potassium Channels; Long QT Syndrome; Mutation; Phenylenediamines | 2010 |
Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.
Topics: Anticonvulsants; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epilepsy; Humans; Phenylenediamines; Randomized Controlled Trials as Topic; Seizures | 2011 |
[New antiepileptic drugs, and therapeutic considerations].
Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Epilepsy; Humans; Lacosamide; Phenylenediamines | 2011 |
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; Rats; Treatment Outcome | 2012 |
Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Drug Interactions; Epilepsy; Humans; Lacosamide; Phenylenediamines | 2012 |
Recent and future antiepileptic drugs and their impact on cognition: what can we expect?
Topics: Acetamides; Animals; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Epilepsy; Forecasting; Humans; Lacosamide; Phenylenediamines | 2012 |
Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Membrane Transport Modulators; Phenylenediamines | 2012 |
ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
Topics: Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; Potassium Channels; Randomized Controlled Trials as Topic; Seizures; United States; United States Food and Drug Administration | 2012 |
Ezogabine: development and role in the management of epileptic seizures.
Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Epilepsy; Half-Life; Humans; Phenylenediamines; Potassium Channels | 2013 |
Recent developments on KCNQ potassium channel openers.
Topics: Acrylamides; Aminopyridines; Benzamides; Carbamates; Epilepsy; Humans; Indoles; Ion Channel Gating; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Migraine Disorders; Oxindoles; Pain; Phenylenediamines; Potassium Channels, Voltage-Gated | 2005 |
Retigabine: chemical synthesis to clinical application.
Topics: Animals; Anticonvulsants; Anxiety; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Humans; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Neurons; Pain; Phenylenediamines; Potassium Channels, Voltage-Gated; Time Factors | 2005 |
Retigabine.
Topics: Animals; Anticonvulsants; Brain; Carbamates; Clinical Trials as Topic; Epilepsy; Humans; Phenylenediamines | 2007 |
Is there a role for potassium channel openers in neuronal ion channel disorders?
Topics: Aminopyridines; Animals; Anticonvulsants; Antihypertensive Agents; Ataxia; Carbamates; Diazoxide; Epilepsy; Humans; Ion Channels; Isaacs Syndrome; Membrane Potentials; Mice; Mice, Neurologic Mutants; Mutation; Nervous System Diseases; Neuroprotective Agents; Parkinson Disease; Phenylenediamines; Potassium Channels | 2000 |
Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.
Topics: Animals; Anticonvulsants; Carbamates; Clinical Trials as Topic; Drug Design; Epilepsy; Epilepsy, Benign Neonatal; Humans; Mutation; Neurons; Phenylenediamines; Potassium Channels; Potassium Channels, Voltage-Gated; Receptors, Muscarinic; Synaptic Transmission | 2001 |
34 other study(ies) available for ezogabine and Aura
Article | Year |
---|---|
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.
Topics: Adamantane; Animals; Azides; Epilepsy; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Mice; Neuralgia; Structure-Activity Relationship | 2010 |
Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Cricetinae; Cricetulus; Drug Design; Epilepsy; Humans; KCNQ Potassium Channels; Patch-Clamp Techniques; Pyrazoles; Pyrimidines; Rubidium; Structure-Activity Relationship | 2011 |
Discovery of a novel Kv7 channel opener as a treatment for epilepsy.
Topics: Animals; Cell Line; Dose-Response Relationship, Drug; Drug Discovery; Electroshock; Epilepsy; Humans; Ion Channel Gating; KCNQ2 Potassium Channel; Microsomes; Molecular Structure; Piperidines; Pyrimidines; Rats; Structure-Activity Relationship | 2015 |
Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Humans; KCNQ Potassium Channels; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Epilepsy; Exercise Test; KCNQ Potassium Channels; Mice; Molecular Structure; Phenylbutyrates; Potassium Channel Blockers; Rats; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution | 2018 |
Novel K
Topics: Animals; Anticonvulsants; Epilepsy; Humans; KCNQ Potassium Channels; Mice; Muscle Contraction; Muscle, Smooth; Protein Isoforms; Seizures; Urinary Bladder | 2018 |
Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development.
Topics: Anticonvulsants; Child; Drugs, Investigational; Epilepsy; Humans; Research Report | 2022 |
Efficacy of antiseizure medication in a mouse model of HCN1 developmental and epileptic encephalopathy.
Topics: Animals; Anticonvulsants; Epilepsy; Epilepsy, Generalized; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Lamotrigine; Mice; Potassium Channels; Seizures; Valproic Acid | 2023 |
Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy.
Topics: Child, Preschool; Epilepsy; Epilepsy, Generalized; Humans; Infant; KCNQ2 Potassium Channel; Mutation; Retrospective Studies; Seizures | 2023 |
An Electrochemophysiological Microarray for Real-Time Monitoring and Quantification of Multiple Ions in the Brain of a Freely Moving Rat.
Topics: Animals; Anticonvulsants; Brain; Calcium; Carbamates; Diamines; Electrochemical Techniques; Epilepsy; Hydrogen-Ion Concentration; Ionophores; Limit of Detection; Male; Microelectrodes; Monitoring, Physiologic; Phenylenediamines; Potassium; Rats, Wistar; Sodium; Zonisamide | 2020 |
Functional and behavioral signatures of Kv7 activator drug subtypes.
Topics: Anilides; Animals; Animals, Genetically Modified; Anticonvulsants; Bridged Bicyclo Compounds; Calcium; Carbamates; Disease Models, Animal; Drug Resistance; Epilepsy; In Vitro Techniques; KCNQ Potassium Channels; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Luminescent Proteins; Membrane Potentials; Mutation; Neurons; Optical Imaging; Patch-Clamp Techniques; Phenylenediamines; Seizures; Zebrafish | 2020 |
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy.
Topics: Age of Onset; Animals; Anticonvulsants; Carbamates; Cells, Cultured; Child; CHO Cells; Cricetinae; Cricetulus; Electroencephalography; Epilepsy; Female; Gabapentin; Humans; KCNQ2 Potassium Channel; Mutation; Phenylenediamines; Precision Medicine; Rats; Treatment Outcome | 2020 |
Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
Topics: Animals; Anticonvulsants; Atrioventricular Block; Behavior, Animal; Bradycardia; Carbamates; Channelopathies; Death, Sudden; Disease Models, Animal; Drug Resistance; Drug Resistant Epilepsy; Electroencephalography; Epilepsy; Gene Expression Profiling; Heart Rate; KCNQ Potassium Channels; KCNQ1 Potassium Channel; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Kv1.1 Potassium Channel; Mice; Nerve Tissue Proteins; Pharmacogenetics; Pharmacogenomic Testing; Phenylenediamines; RNA, Messenger; Transcriptome | 2018 |
Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
Topics: Animals; Anticonvulsants; Carbamates; CHO Cells; Cricetinae; Cricetulus; Epilepsy; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Keratolytic Agents; Mice; Mutation; Nerve Tissue Proteins; Neurons; Organometallic Compounds; Phenylenediamines; Phosphatidylinositol 4,5-Diphosphate; Pyridines; Signal Transduction | 2013 |
The preclinical discovery and development of ezogabine for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Drug Discovery; Epilepsy; Humans; Phenylenediamines; Product Surveillance, Postmarketing | 2013 |
Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
Topics: Action Potentials; Animals; Anticonvulsants; CA1 Region, Hippocampal; Carbamates; Carbamazepine; Disease Models, Animal; Epilepsy; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Net; Organ Culture Techniques; Phenylenediamines; Up-Regulation; Voltage-Gated Sodium Channel beta-1 Subunit | 2014 |
Long term retention of retigabine in a cohort of people with drug resistant epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Drug Resistance; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Phenylenediamines; Piracetam; Time; Treatment Outcome; Young Adult | 2014 |
A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Cohort Studies; Epilepsy; Female; Humans; Intellectual Disability; Male; Middle Aged; Phenylenediamines; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Topics: Animals; Animals, Newborn; Anticonvulsants; Carbamates; Disease Models, Animal; Epilepsy; Evoked Potentials, Auditory, Brain Stem; Female; HEK293 Cells; Homeodomain Proteins; Humans; In Vitro Techniques; KCNQ Potassium Channels; KCNQ2 Potassium Channel; Male; Membrane Potentials; Mice; Mice, Inbred ICR; Mice, Knockout; Mutation; Phenylenediamines; Rats; Rats, Sprague-Dawley; Tinnitus; Transcription Factors | 2015 |
Targeting Kv7 channels in pain pathways.
Topics: Aminopyridines; Animals; Carbamates; Deafness; Epilepsy; Humans; Inflammation; KCNQ Potassium Channels; Long QT Syndrome; Mutation; Neurons; Pain; Pain Management; Phenylenediamines; Protein Conformation | 2017 |
Deal watch: GSK acquires rights to Valeant's anti-epileptic drug.
Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Commerce; Drug Industry; Epilepsy; Legislation, Drug; Phenylenediamines | 2008 |
The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Drug Synergism; Epilepsy; Humans; KCNQ Potassium Channels; Neurons; Phenylenediamines; Treatment Outcome | 2012 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brain Stimulation; Dopamine Agonists; Epilepsy; Fingolimod Hydrochloride; Genetic Therapy; Humans; Immunosuppressive Agents; Ischemic Attack, Transient; Multiple Sclerosis; Muscular Diseases; Neurology; Parkinson Disease; Phenylenediamines; Polyneuropathies; Propylene Glycols; Sphingosine; Stroke; Treatment Outcome; Valproic Acid | 2012 |
Retigabine: fewer drug interactions.
Topics: Anticonvulsants; Carbamates; Drug Interactions; Drug Therapy, Combination; Epilepsy; Humans; Phenylenediamines; Randomized Controlled Trials as Topic | 2012 |
Anticonvulsant effect of retigabine during postnatal development in rats.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Carbamates; Convulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Injections, Subcutaneous; Kindling, Neurologic; Pentylenetetrazole; Phenylenediamines; Pregnancy; Rats; Rats, Sprague-Dawley; Seizures | 2012 |
Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat.
Topics: Animals; Anticonvulsants; Apoptosis; Biomarkers; Carbamates; Caspase Inhibitors; Dizocilpine Maleate; Enzyme Inhibitors; Epilepsy; Female; Hippocampus; Limbic System; Neuroprotective Agents; Phenylenediamines; Rats; Rats, Wistar; Sclerosis; Status Epilepticus; Time Factors | 2002 |
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Epilepsy; Felbamate; Fructose; Gabapentin; gamma-Aminobutyric Acid; Guinea Pigs; Hippocampus; In Vitro Techniques; Levetiracetam; Male; Phenylcarbamates; Phenylenediamines; Piracetam; Propylene Glycols; Soman; Topiramate | 2005 |
Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Carbamates; Disease Models, Animal; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Epilepsy; Hippocampus; Kindling, Neurologic; Male; Motor Activity; Phenylenediamines; Rats; Rats, Wistar; Time Factors | 2008 |
Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response.
Topics: Animals; Anticonvulsants; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Female; Male; Phenylenediamines; Rats; Rats, Inbred Strains | 1995 |
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
Topics: Acetamides; Animals; Anticonvulsants; Azetidines; Carbamates; Drug Evaluation, Preclinical; Drugs, Investigational; Epilepsy; Humans; Israel; Levetiracetam; Nipecotic Acids; Phenylenediamines; Piracetam; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Thiazoles; Tiagabine; Triazoles | 1996 |
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; Carbamates; Convulsants; Electrophysiology; Entorhinal Cortex; Epilepsy; Excitatory Amino Acid Antagonists; In Vitro Techniques; Phenylenediamines; Rats; Rats, Wistar; Seizures | 1999 |
Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells.
Topics: Animals; Anticonvulsants; Carbamates; Cells, Cultured; Electrophysiology; Epilepsy; Nerve Growth Factor; PC12 Cells; Phenylenediamines; Potassium Channels; Rats | 1999 |
The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.
Topics: Animals; Anticonvulsants; Calcium; Carbamates; Electrophysiology; Epilepsy; gamma-Aminobutyric Acid; Hippocampus; In Vitro Techniques; Magnesium Deficiency; Male; Phenylenediamines; Potassium Channels; Rats; Rats, Wistar | 2000 |
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Electroencephalography; Entorhinal Cortex; Epilepsy; Hippocampus; Magnesium Deficiency; Phenylenediamines; Rats; Rats, Wistar | 2000 |